Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML

BACKGROUND: NPM1 mutation status can influence prognosis and management in AML. Accordingly, clinical testing (i.e., RT-PCR, NGS and IHC) for mutant NPM1 is increasing in order to detect residual disease in AML, alongside flow cytometry (FC). However, the relationship of the results from RT-PCR to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez, Amanda, Patel, Sanjay, Geyer, Julia T., Racchumi, Joelle, Chadburn, Amy, Simonson, Paul, Ouseph, Madhu M., Inghirami, Giorgio, Mencia-Trinchant, Nuria, Guzman, Monica L., Gomez-Arteaga, Alexandra, Lee, Sangmin, Desai, Pinkal, Ritchie, Ellen K., Roboz, Gail J., Tam, Wayne, Kluk, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435844/
https://www.ncbi.nlm.nih.gov/pubmed/34527579
http://dx.doi.org/10.3389/fonc.2021.701318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435844/
https://www.ncbi.nlm.nih.gov/pubmed/34527579
http://dx.doi.org/10.3389/fonc.2021.701318

Ejemplares similares